Clostridioides difficile infection (CDI) is the most lethal of the five CDC urgent public health
treats, resulting in 12,800 annual deaths in the United States alone [Antibiotic Resistance …

Abstract Scope In 2009, the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) published the first treatment guidance document for Clostridioides …

Background Diarrhea and pseudomembranous colitis associated with Clostridioides difficile–
a spore-forming anaerobic Gram-positive bacillus–is a major infection in hospitalized …

With current first-in-line antibiotic therapy options associated with high levels of recurrent
CDI, the availability of new generation targeted therapeutics can really impact treatment …

One of the main clinical challenges of Clostridium difficile infections (CDI) is the high rate of
relapse episodes. The main determinants involved in relapse of CDI include the presence of …

Clostridioides difficile infection (CDI) is one of the major issues in nosocomial infections.
This bacterium is constantly evolving and poses complex challenges for clinicians, often …

Background Although many large, randomized controlled trials (RCT) have been conducted
on antibiotic therapy for patients with primary C. difficile infections (CDI), few RCTs have …

The beneficial effect of colonization of the gastrointestinal tract by non-toxigenic
Clostridioides difficile (NTCD) strains as a preventive of toxigenic C. difficile infection (CDI) …

Guidelines for the diagnosis and treatment of Clostridioides difficile infection have recently
been updated. Risk factors include recent exposure to health care facilities or antibiotics …

Clostridioides difficile spores produced during infection are important for the recurrence of
the disease. Here, we show that C. difficile spores gain entry into the intestinal mucosa via …